Pharmalink readies for PhIII on 'astonishing' glomerulonephritis data

Pharmalink of Sweden is basking in the "astonishingly good" Phase IIb data of Nefecon, its oral modified-release capsule of budesonide, in the treatment of primary IgA nephropathy – the most common form of glomerulonephritis. The NEFIGEN trial met its primary endpoint at a planned interim analysis and has been stopped early with respect to statistical analysis of the endpoint.

IgA nephropathy is an autoimmune renal disease characterized by deposits, predominantly containing polymeric IgA antibody, in the kidney that cause inflammation and renal damage